Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine

J Eur Acad Dermatol Venereol. 2021 Nov;35(11):e743-e745. doi: 10.1111/jdv.17549. Epub 2021 Aug 10.

Authors

A Smola¹, S Samadzadeh², L Müller³, O Adams³, B Homey¹, P Albrecht², S Meller¹

Affiliations

¹ Department of Dermatology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
² Department of Neurology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
³ Institute of Virology, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.

No abstract available

Publication types

Letter

MeSH terms

Anaphylaxis* / chemically induced
Anaphylaxis* / prevention & control
COVID-19 Vaccines
COVID-19*
Humans
Omalizumab / adverse effects
RNA, Messenger
SARS-CoV-2

Substances

COVID-19 Vaccines
RNA, Messenger
Omalizumab